About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3623749
Allelic
Composition
Lepob/Lepob
Genetic
Background
B6.Cg-Lepob/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lepob mutation (6 available); any Lep mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Lepob/Lepob

growth/size/body
• mice have fat mass of ~42 g compared to ~3 g in wild-type at 16 weeks (J:122746)
• mice have fat mass of ~42 g compared to ~3 g in wild-type at 16 weeks (J:122746)
• treatment with triiodothyronine significantly reduces body weight relative to the reduction seen in controls (J:22025)
• treatment with triiodothyronine significantly reduces body weight relative to the reduction seen in controls (J:22025)
• body weight reduced by treatment with Leptin (J:29075)
• body weight reduced by treatment with Leptin (J:29075)
• develop progressive obesity (J:103063)
• develop progressive obesity (J:103063)
• 12-week old males are obese (J:104171)
• 12-week old males are obese (J:104171)
• mice reach 60-70 g by 10 months of age (J:5400)
• mice reach 60-70 g by 10 months of age (J:5400)

homeostasis/metabolism
• leptin-treated islet cells exhibit decreased insulin secretion compared to similarly treated wild-type islets (J:145998)
• leptin-treated islet cells exhibit decreased insulin secretion compared to similarly treated wild-type islets (J:145998)
• insulin content in the pancreata is increased compared to in wild-type mice (J:145998)
• insulin content in the pancreata is increased compared to in wild-type mice (J:145998)
• after feeding, serum glucose levels are more than 30% lower than in wild-type mice (J:145998)
• after feeding, serum glucose levels are more than 30% lower than in wild-type mice (J:145998)
• older mice are usually hypoglycemic (J:5400)
• older mice are usually hypoglycemic (J:5400)
• transient hyperglycemia (J:5400)
• blood sugar peaks at 2-3 months (J:5400)
• returns to normal by 4-5 months of age (J:5400)
• transient hyperglycemia (J:5400)
• blood sugar peaks at 2-3 months (J:5400)
• returns to normal by 4-5 months of age (J:5400)
• Background Sensitivity: homozygotes exhibit a mild, transient hyperglycemia between 10-14 weeks of age as compared to the severe, progressive hyperglycemia observed on the BTBR background (J:65486)
• mice infrequently transition to severe hyperglycemia (J:65486)
• Background Sensitivity: homozygotes exhibit a mild, transient hyperglycemia between 10-14 weeks of age as compared to the severe, progressive hyperglycemia observed on the BTBR background (J:65486)
• mice infrequently transition to severe hyperglycemia (J:65486)
• serum glucose is 320 mg/dl compared to 134 mg/dl in wild-type controls (J:122746)
• serum glucose is 320 mg/dl compared to 134 mg/dl in wild-type controls (J:122746)
• males exhibit elevated blood glucose levels (254.4 +/-33.7 mg/dl) as compared to wild-type between 20-22 weeks of age (J:185261)
• Background Sensitivity: blood glucose levels are lower than obese mice on the BTBR background (J:185261)
• males exhibit elevated blood glucose levels (254.4 +/-33.7 mg/dl) as compared to wild-type between 20-22 weeks of age (J:185261)
• Background Sensitivity: blood glucose levels are lower than obese mice on the BTBR background (J:185261)
• insulin levels increase rapidly to over 50X normal controls (J:5400)
• insulin levels increase rapidly to over 50X normal controls (J:5400)
• seen in 12-week old males (J:104171)
• seen in 12-week old males (J:104171)
• serum insulin is 41.5 ng/ml compared to 0.8 ng/ml in wild-type (J:122746)
• serum insulin is 41.5 ng/ml compared to 0.8 ng/ml in wild-type (J:122746)
• at 2 weeks, insulin levels are increased 2.5-fold compared to in wild-type mice (J:145998)
• however, mice treated with isoproterenol exhibit lowered serum levels of insulin (J:145998)
• at 2 weeks, insulin levels are increased 2.5-fold compared to in wild-type mice (J:145998)
• however, mice treated with isoproterenol exhibit lowered serum levels of insulin (J:145998)
• fasting plasma total cholesterol concentration is increased 2-3 fold over controls (J:18161)
• fasting plasma total cholesterol concentration is increased 2-3 fold over controls (J:18161)
• triglyceride levels are elevated 1.5- to 2-fold (J:18161)
• triglyceride levels are elevated 1.5- to 2-fold (J:18161)
• seen in 12-week old males (J:104171)
• seen in 12-week old males (J:104171)
• body temperature is maintained a basal level when the ambient temperature is gradually reduced to 4C (J:129662)
• body temperature is maintained a basal level when the ambient temperature is gradually reduced to 4C (J:129662)
• oxygen consumption about 2/3 that observed in controls (J:22025)
• increased by treatment with triiodothyronine (J:22025)
• increased by treatment with triiodothyronine (J:22025)
• oxygen consumption about 2/3 that observed in controls (J:22025)
• insulin stimulated oxygen consumption by the soleus muscle is little affected by triiodothyronine (J:22377)
• insulin stimulated oxygen consumption by the soleus muscle is little affected by triiodothyronine (J:22377)
• in the epididymal and brown fat pads (J:22377)
• in the epididymal and brown fat pads (J:22377)
• in the liver (J:22377)
• in the liver (J:22377)
• glucose intolerance which improved when treated with rosiglitazone (J:107486)
• following an acute intraperitoneal glucose injection, the post-challenge glucose level remained elevated up to 120 min compared to controls, indicating glucose intolerance (J:107486)
• glucose intolerance which improved when treated with rosiglitazone (J:107486)
• following an acute intraperitoneal glucose injection, the post-challenge glucose level remained elevated up to 120 min compared to controls, indicating glucose intolerance (J:107486)
• total body protein lower than in controls (J:22025)
• total body protein increased by treatment with triiodothyronine (J:22025)
• total body protein lower than in controls (J:22025)
• total body protein increased by treatment with triiodothyronine (J:22025)
• males show elevated levels of serotonin and 5'hydroxyindolineacetic acid in urine (J:4033)
• males show elevated levels of serotonin and 5'hydroxyindolineacetic acid in urine (J:4033)
• less epinephrine in the urine of ad libitum fed mice (J:4033)
• urine levels of norepinephrine only slightly elevated (J:4033)
• males show elevated levels of dopamine in urine (J:4033)
• less epinephrine in the urine of ad libitum fed mice (J:4033)
• urine levels of norepinephrine only slightly elevated (J:4033)
• males show elevated levels of dopamine in urine (J:4033)

cardiovascular system
• exhibit myocyte hypertrophy, with increased myocyte diameter and distorted nuclear architecture (J:103063)
• exhibit myocyte hypertrophy, with increased myocyte diameter and distorted nuclear architecture (J:103063)
• exhibit extensive focal damage in myocardial tissue, showing an abundance of lipid droplets in myocytes and damaged mitochondria that are swelled, have disorganized cristae and show loss of integrity (J:104171)
• exhibit extensive focal damage in myocardial tissue, showing an abundance of lipid droplets in myocytes and damaged mitochondria that are swelled, have disorganized cristae and show loss of integrity (J:104171)
• cardiomyocytes exhibit a significantly enlarged cross-sectional area (J:111488)
• cardiomyocytes exhibit a significantly enlarged cross-sectional area (J:111488)
• cardiomyocytes display larger resting cell length and cross-sectional area (J:104171)
• cardiomyocytes display larger resting cell length and cross-sectional area (J:104171)
• increase in left ventricle wall thickness and mass is seen by 6 months of age but not at 2 months of age (J:103063)
• induced weight loss via leptin infusion, but not via caloric restriction, partially resolves the hypertrophy (J:103063)
• increase in left ventricle wall thickness and mass is seen by 6 months of age but not at 2 months of age (J:103063)
• induced weight loss via leptin infusion, but not via caloric restriction, partially resolves the hypertrophy (J:103063)
• exhibit cardiac contractile dysfunction that is due to leptin deficiency and not obesity as high fat diet-induced obese controls show normal cardiomyocyte morphology and contractile function (J:104171)
• exhibit cardiac contractile dysfunction that is due to leptin deficiency and not obesity as high fat diet-induced obese controls show normal cardiomyocyte morphology and contractile function (J:104171)
• cardiomyocytes exhibit a reduced contractile capacity (J:111488)
• decreased peak shortening (J:111488)
• prolonged relengthening (J:111488)
• elevated resting peak calcium ion concentration (J:111488)
• slowed intracellular calcium ion decay (J:111488)
• cardiomyocytes exhibit a reduced contractile capacity (J:111488)
• decreased peak shortening (J:111488)
• prolonged relengthening (J:111488)
• elevated resting peak calcium ion concentration (J:111488)
• slowed intracellular calcium ion decay (J:111488)
• cardiomyocytes exhibit decreased peak shortening and maximal velocity of shortening/relengthening, prolonged time-to-90% relengthening, reduced intracellular calcium release upon electrical stimulus associated with a slowed intracellular calcium decay rate, and significantly higher oxygen levels (J:104171)
• cardiomyocytes exhibit decreased peak shortening and maximal velocity of shortening/relengthening, prolonged time-to-90% relengthening, reduced intracellular calcium release upon electrical stimulus associated with a slowed intracellular calcium decay rate, and significantly higher oxygen levels (J:104171)

muscle
• exhibit cardiac contractile dysfunction that is due to leptin deficiency and not obesity as high fat diet-induced obese controls show normal cardiomyocyte morphology and contractile function (J:104171)
• exhibit cardiac contractile dysfunction that is due to leptin deficiency and not obesity as high fat diet-induced obese controls show normal cardiomyocyte morphology and contractile function (J:104171)
• cardiomyocytes exhibit a reduced contractile capacity (J:111488)
• decreased peak shortening (J:111488)
• prolonged relengthening (J:111488)
• elevated resting peak calcium ion concentration (J:111488)
• slowed intracellular calcium ion decay (J:111488)
• cardiomyocytes exhibit a reduced contractile capacity (J:111488)
• decreased peak shortening (J:111488)
• prolonged relengthening (J:111488)
• elevated resting peak calcium ion concentration (J:111488)
• slowed intracellular calcium ion decay (J:111488)
• muscle protein content is reduced (J:151518)
• muscle protein content is reduced (J:151518)
• exhibit myocyte hypertrophy, with increased myocyte diameter and distorted nuclear architecture (J:103063)
• exhibit myocyte hypertrophy, with increased myocyte diameter and distorted nuclear architecture (J:103063)
• exhibit extensive focal damage in myocardial tissue, showing an abundance of lipid droplets in myocytes and damaged mitochondria that are swelled, have disorganized cristae and show loss of integrity (J:104171)
• exhibit extensive focal damage in myocardial tissue, showing an abundance of lipid droplets in myocytes and damaged mitochondria that are swelled, have disorganized cristae and show loss of integrity (J:104171)
• cardiomyocytes exhibit a significantly enlarged cross-sectional area (J:111488)
• cardiomyocytes exhibit a significantly enlarged cross-sectional area (J:111488)
• cardiomyocytes display larger resting cell length and cross-sectional area (J:104171)
• cardiomyocytes display larger resting cell length and cross-sectional area (J:104171)
• cross-sectional area of muscle fibers is generally smaller (J:151518)
• cross-sectional area of muscle fibers is generally smaller (J:151518)
• lower proportion of faster myosin heavy chain isoforms (J:151518)
• lower proportion of faster myosin heavy chain isoforms (J:151518)
• mean muscle mass consistently less than controls but magnitude of difference is muscle specific (J:151518)
• mean muscle mass consistently less than controls but magnitude of difference is muscle specific (J:151518)

adipose tissue
• treatment with triiodothyronine significantly reduces adipocyte numbers relative to the degree of reduction seen in controls (J:22377)
• treatment with triiodothyronine reduces adipocyte numbers (J:22377)
• treatment with triiodothyronine significantly reduces adipocyte numbers relative to the degree of reduction seen in controls (J:22377)
• treatment with triiodothyronine reduces adipocyte numbers (J:22377)
• mice have fat mass of ~42 g compared to ~3 g in wild-type at 16 weeks (J:122746)
• mice have fat mass of ~42 g compared to ~3 g in wild-type at 16 weeks (J:122746)
• treatment with triiodothyronine significantly reduces epididymal fat pad weight relative to the degree of reduction seen in controls (J:22377)
• adipocyte size remains larger after treatment with triiodothyronine relative to controls (J:22377)
• treatment with triiodothyronine significantly reduces epididymal fat pad weight relative to the degree of reduction seen in controls (J:22377)
• adipocyte size remains larger after treatment with triiodothyronine relative to controls (J:22377)
• greater weight than for controls (J:22377)
• affected less by treatment with triiodothyronine than controls (J:22377)
• brown adipocyte numbers are normal (J:22377)
• greater weight than for controls (J:22377)
• affected less by treatment with triiodothyronine than controls (J:22377)
• brown adipocyte numbers are normal (J:22377)

behavior/neurological
• food intake is reduced by Leptin treatment (J:29075)
• food intake is reduced by Leptin treatment (J:29075)
• increased food intake when ambient temperature drops from 28 to 21C (J:129662)
• increased food intake when ambient temperature drops from 28 to 21C (J:129662)
• mice eat 70% more than wild-type controls (J:122746)
• mice eat 70% more than wild-type controls (J:122746)
• less wheel running activity (J:115771)
• more wheel running activity in light phase and less in dark phase (J:115771)
• less wheel running activity (J:115771)
• more wheel running activity in light phase and less in dark phase (J:115771)
• significantly reduced activity relative to wild-type controls (J:122746)
• significantly reduced activity relative to wild-type controls (J:122746)
• resistant to tactile allodynia caused by partial sciatic nerve ligation (J:152019)
• epineural application of leptin treated peritoneal macrophage induces tactile allodynia (J:152019)
• resistant to tactile allodynia caused by partial sciatic nerve ligation (J:152019)
• epineural application of leptin treated peritoneal macrophage induces tactile allodynia (J:152019)
• display thermal hyperalgesia after partial sciatic nerve ligation (J:152019)
• display thermal hyperalgesia after partial sciatic nerve ligation (J:152019)
• increased total sleep time in a 24 hour period (J:115771)
• additional sleep primarily in the dark phase (J:115771)
• increased non-REM sleep time (J:115771)
• recovery from sleep deprivation involves increased duration of non-REM bouts rather than increased number of bouts as seen in controls (J:115771)
• increased total sleep time in a 24 hour period (J:115771)
• additional sleep primarily in the dark phase (J:115771)
• increased non-REM sleep time (J:115771)
• recovery from sleep deprivation involves increased duration of non-REM bouts rather than increased number of bouts as seen in controls (J:115771)
• reduced REM in light phase (J:115771)
• increased REM in dark phase (J:115771)
• reduced REM in light phase (J:115771)
• increased REM in dark phase (J:115771)
• sleep more fragmented (J:115771)
• more arousals (J:115771)
• shorter wake periods (J:115771)
• sleep more fragmented (J:115771)
• more arousals (J:115771)
• shorter wake periods (J:115771)

reproductive system
• females do not produce litters (J:122746)
• females do not produce litters (J:122746)

respiratory system
• ozone induces significantly elevated levels of TNFR1 (J:115772)
• ozone induces a nonsignificant elevation of TNFR2 levels (J:115772)
• ozone induces significantly elevated levels of TNFR1 (J:115772)
• ozone induces a nonsignificant elevation of TNFR2 levels (J:115772)

endocrine/exocrine glands
• Background Sensitivity: less beta cell degranulation than seen on the "BKS" background (J:5400)
• Background Sensitivity: less beta cell degranulation than seen on the "BKS" background (J:5400)
• leptin-treated islet cells exhibit decreased insulin secretion compared to similarly treated wild-type islets (J:145998)
• leptin-treated islet cells exhibit decreased insulin secretion compared to similarly treated wild-type islets (J:145998)
• insulin content in the pancreata is increased compared to in wild-type mice (J:145998)
• insulin content in the pancreata is increased compared to in wild-type mice (J:145998)

renal/urinary system
• males show elevated levels of serotonin and 5'hydroxyindolineacetic acid in urine (J:4033)
• males show elevated levels of serotonin and 5'hydroxyindolineacetic acid in urine (J:4033)
• less epinephrine in the urine of ad libitum fed mice (J:4033)
• urine levels of norepinephrine only slightly elevated (J:4033)
• males show elevated levels of dopamine in urine (J:4033)
• less epinephrine in the urine of ad libitum fed mice (J:4033)
• urine levels of norepinephrine only slightly elevated (J:4033)
• males show elevated levels of dopamine in urine (J:4033)

immune system
• reduced numbers can be restored by treatment with leptin (J:117826)
• reduced numbers can be restored by treatment with leptin (J:117826)
• ozone induces significantly elevated levels of TNFR1 (J:115772)
• ozone induces a nonsignificant elevation of TNFR2 levels (J:115772)
• ozone induces significantly elevated levels of TNFR1 (J:115772)
• ozone induces a nonsignificant elevation of TNFR2 levels (J:115772)

tumorigenesis
• increased metastasis to the lung of both melanoma cell lines and lung cancer cell lines initially injected in the tail vein (J:117826)
• leptin reduces the level of metastasis (J:117826)
• increased metastasis to the lung of both melanoma cell lines and lung cancer cell lines initially injected in the tail vein (J:117826)
• leptin reduces the level of metastasis (J:117826)

hematopoietic system
• reduced numbers can be restored by treatment with leptin (J:117826)
• reduced numbers can be restored by treatment with leptin (J:117826)

nervous system

liver/biliary system
• treatment with triiodothyronine significantly reduces relative and absolute liver weight (J:22377)
• treatment with triiodothyronine significantly reduces relative and absolute liver weight (J:22377)

integument
• resistant to tactile allodynia caused by partial sciatic nerve ligation (J:152019)
• epineural application of leptin treated peritoneal macrophage induces tactile allodynia (J:152019)
• resistant to tactile allodynia caused by partial sciatic nerve ligation (J:152019)
• epineural application of leptin treated peritoneal macrophage induces tactile allodynia (J:152019)
• display thermal hyperalgesia after partial sciatic nerve ligation (J:152019)
• display thermal hyperalgesia after partial sciatic nerve ligation (J:152019)

skeleton
• bone marrow is almost completely replaced with mature adipocytes (J:189019)
• bone marrow is almost completely replaced with mature adipocytes (J:189019)

Mouse Models of Human Disease
OMIM ID Ref(s)
Obesity 601665 J:103063 , J:104171


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
01/26/2016
MGI 6.02
The Jackson Laboratory